At utR Biotech, we are developing a next-generation treatment that restores how the body naturally manages blood sugar, energy, and long-term metabolic health. In a healthy pancreas, insulin is always released together with a companion molecule—a small protein. Modern insulin products leave this protein out entirely. Our research shows that this missing piece is not optional: it is essential for healthy signaling throughout the body.
Why pairing insulin with “the protein” matters
In nature, insulin and this protein are released in equal amounts. Insulin lowers blood sugar, while the protein controls deeper metabolic processes that protect the heart, kidneys, nerves, and blood vessels.
Our patent reveals that the protein communicates with three different receptors in the body, each playing a unique role:
- Insulin receptor: The protein helps insulin work more efficiently and for longer.
- A metabolic receptor (GPR146): The protein can “switch off” harmful stress-hormone signals and excessive fat and cholesterol production.
- A repair-and-protection receptor (RXFP1): This receptor supports anti-inflammatory and anti-fibrotic processes that protect organs like the kidneys and heart.
By restoring these natural signals, the co-formulation supports whole-body metabolic balance in a way insulin alone cannot.
A coordinated therapy for long-term diabetic complications
Without the protein, insulin treatment only covers blood sugar—while hidden problems continue unchecked:
- Reduced blood flow in small vessels
- Inflammation and tissue stress
- Accelerated nerve damage
- Kidney strain
- High cholesterol and lipid abnormalities
- Elevated cortisol (stress hormone)
- Mitochondrial dysfunction
Our co-formulation addresses these deeper issues by restoring the natural teamwork between insulin and its companion protein. This helps re-establish normal microcirculation, reduce inflammation, protect nerves, and restore healthy fat- and cholesterol-regulation pathways.
Breakthrough mass efficiency—7× less drug required
Because the protein strengthens and prolongs insulin’s action, the combined therapy is about seven times more mass-efficient than insulin alone. This means:
- Smaller injection volumes
- Lower total drug exposure
- Lower manufacturing costs
- A more natural and stable therapeutic effect
This efficiency is based on measured differences in molecular weight, binding strength, and how long each molecule lasts in the bloodstream.
A new pathway for Alzheimer’s protection
The patented formulation also shows promise for brain health. The protein activates protective pathways in nerve cells that:
- Reduce the production of harmful amyloid-beta
- Support natural clearing of existing amyloid plaques
- Lower stress-hormone–driven damage inside the brain
- Promote protective enzymes controlled by SIRT1, a key longevity molecule
These combined effects form a dual-action strategy for slowing Alzheimer’s progression—something no existing diabetes therapy provides.
Precision-medicine ready
Our patent also introduces a diagnostic method: a simple blood test that measures the relationship between cortisol and the protein. This ratio helps identify patients who will benefit most from the therapy. It supports a future in which diabetes treatment is not “one size fits all,” but tailored to each person’s biology.
Designed for modern manufacturing
Our formulation is compatible with standard pharmaceutical processes, stable in both liquid and freeze-dried formats, and suitable for rapid advancement through the FDA’s 505(b)(2) pathway.